Alveus Therapeutics

Philadelphia, PA · Founded 2023 · Privately Held (backing)

Developer of biological and small-molecule treatments designed for metabolic disease management. Alveus Therapeutics is based in Philadelphia, PA and was founded in 2023. It was valued at $275 million at its early-stage round in Feb 2026, the last priced event on record. It has raised $202 million across 1 recorded round; the latest was a $56.9 million later-stage round in Dec 2025.

PMV mark · valuation
$275.2M
Oct 2026
Priced at
its early-stage round
Feb 2026
Total raised
$202.0M
Last round
Later Stage VC
Dec 2025

Who backs Alveus Therapeutics?

13 investors
InvestorType
Novo HoldingsOther
Kurma PartnersVenture capital
Andera PartnersPE / buyout
Omega FundsPE / buyout
Agent Capital—
Avego Management—
Global BioAccess Fund—
Jeito—
Lotte Holdings (Japan)—
New Rhein Healthcare—
+ 3 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Alveus Therapeutics investors

13 investors are on record for Alveus Therapeutics, including Novo Holdings, Kurma Partners, Andera Partners and Omega Funds. The later-stage round in Dec 2025 drew 17 investors.

Free account
More of Alveus Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Alveus Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 13 firms already write checks for companies like Alveus Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View